Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2025

Genmab — September 2025

Planlagt Fastgjort Låst Flyttet Genmab
283 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #75

    " With a median follow-up of >2 years, the combination of epcoritamab and R2 demonstrated clinically meaningful antitumor activity, with CR rates that, to our knowledge, are higher than any previously published for other bispecific antibody–based regimens in R/R FL"

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #76

      "Analyses based on pLOT showed that the CR rate was higher in the 2L group compared with the group receiving epcoritamab plus R2 in the third line or later, suggesting an advantage to using epcoritamab regimens earlier. Most patients with a poor prognosis, such as those with primary refractory or double-refractory disease, whose FL is typically resistant to common therapies including rituximab, had a CR with epcoritamab plus R2."

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #77

        Scancell Business Update -Second commercial licence with Genmab for SC2811 secured for $6 million in total upfront payments and up to $630 million in potential milestones and low-single digit royalties
        Development of the first Genmab partnered SC129 remains on track with further milestones payments anticipated in the near-term. https://www.globenewswire.com/news-release/2025/09/11/3148321/0/en/Scancell-reports-Business-Update-and-Financial-Results-for-the-Year-Ended-30-April-2025.html

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #78

          EL, you have the best News Service avail. Keep them coming 🙂

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #79

            Jeg synte sgu det køre for Gmab for tiden, det wr godt nok en lettelse oven på alle de måneder med konstant nedgang i prisen. Med en PE under 15 er der luft til mere stigning som helt sikkert kommer med forventede gode data i 2H

            1 Reply Last reply
            0
            • P Offline
              P Offline
              Plimsoller
              wrote on sidst redigeret af
              #80

              Den er steget omkring 55% siden starten / midten af april, så det er absolut godkendt - også selvom det var et billigt udgangspunkt.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #81

                Rinatabart sesutecan
                on the EMA PDCO agenda for a Product Specific Waiver
                in Endometrial cancer (for lahn 😉 )

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #82

                  Thx, they are progressing as expected
                  🙂

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #83

                    Holder på mine bulls. Der er flere gode nyheder i vente de næste måneder.

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #84

                      Ugekommentar: Hvad tænker Helge Larsen om den spareplan, der er kommet fra Novo Nordisk? Skal man sælge eller beholde sine Bavarian Nordic-aktier? Er Genmab i gang med en revival? Kort video: https://proinvestor.com/boards/128333

                      1 Reply Last reply
                      0
                      • R Offline
                        R Offline
                        Raun
                        wrote on sidst redigeret af
                        #85

                        Set i lyset af at Genmab tjener kassen de næste 4 års tid endnu på Darzalex alene, Så er der jo nærmest blue sky scenario over det vi ved af.... Set i lyset af det og set konservativt. - Burde en fair P/E værdi så ikke være mellem 30-35
                        stykker?

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #86

                          Lahn1 har du stadig Zymeworks? Jazz´s seneste investor præsentation igen meget positiv og data udskudt endnu en gang - nu Q1 2026. Svært efterhånden ikke at tro det er gode tegn!

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lahn1
                            wrote on sidst redigeret af
                            #87

                            Yes jegvhar endda lidt for mange, men alt ser lysere ud nu selvom de nedlukkede zw171. Ejwnjw udsludt igen, men ok der er jo ingen cash mangler og det er jo events drevet ik? Så alt ser godt ud

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              lahn1
                              wrote on sidst redigeret af
                              #88

                              Jeg er ikke helt klart på om jeg holder efter zw251 går i klinikken og GEA data. Vil lige høre jazz præsentationen

                              1 Reply Last reply
                              0
                              • L Offline
                                L Offline
                                lahn1
                                wrote on sidst redigeret af
                                #89

                                Shit den er oppe 31% den seneste måned. Syntes det venser for biotech for tiden.

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  peter12
                                  wrote on sidst redigeret af
                                  #90

                                  Iflg Morningstar https://www.morningstar.com/stocks/xcse/gmab/ownership har GMAB fået en ny større investor https://www.orbis.com/us/institutional/insights/commentaries/quarterly/2024/q3/international

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #91

                                    Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff https://seekingalpha.com/article/4822562-genmab-epkinly-spectacular-data-antidote-to-darzalex-patent-cliff

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #92

                                      Genmab: A Matter Of Time https://seekingalpha.com/article/4822275-genmab-a-matter-of-time

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #93

                                        Tak for 2 interessante artikler E L 07:18 / 07:52 og god morgen

                                        1 Reply Last reply
                                        0
                                        • R Offline
                                          R Offline
                                          Raun
                                          wrote on sidst redigeret af
                                          #94

                                          Mange tak for god læsning E L 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper